Table 3.
Compounds | R1 | R2 | R3 |
Ki
(nM)*
|
Antinociceptive properties§ ED50, μg (95% confidence limits) | |
---|---|---|---|---|---|---|
NEP† | APN‡ | |||||
7(B) | CH2Ph | CH2Ph(p-Ph) | CH3 | 2.2 ± 0.3 | 5.3 ± 0.7 | 11 (6.84–17.7) 19.1 nmol |
8(B) | Ph | CH2Ph(p-Ph) | CH3 | 2.0 ± 0.5 | 4.8 ± 0.7 | 10.5 (5.83–18.9) 18.7 nmol |
9(B) | CH3 | CH2Ph(p-Ph) | CH3 | 1.2 ± 0.2 | 2.9 ± 0.3 | 6 (3.66–9.84) 12 nmol |
Values are the mean ± SEM from three independent experiments performed in triplicate of five inhibitor concentrations.
NEP activity was measured by using DGNPA as substrate.
APN activity was measured by using Ala-p.NA as substrate.
Inhibitors were administered ICV 15 min before the plate test.